Friday, August 21, 2009 2:55:50 PM
Does Teva have Shire in its cross-hairs?
http://www.reuters.com/article/innovationNews/idUSTRE57K2G020090821
By Ben Hirschler and Steven Scheer
LONDON/JERUSALEM (Reuters) - Teva Pharmaceutical Industries, the world's biggest generic drugmaker, could turn the tables on its Big Pharma rivals by snapping up Shire, a maker of branded specialty medicines.
That, at least, is the buzz among investors casting around for the next $10 billion-plus transaction in a sector that has seen a wave of deal-making this year.
Buying Shire would make sense for the acquisitive Israeli group, some analysts say, since Teva is looking to shore up its relatively small, yet important, branded business as its multiple sclerosis drug Copaxone faces the threat of generic competition.
Shire, which operates out of Britain and the United States but is based in Dublin for tax purposes, could fit the bill.
Healthcare bankers familiar with the two companies said Shire was an attractive target for Teva, and potentially others, given its line-up of marketed and experimental drugs in specialty medicine, but a deal did not appear to be imminent.
A bid for Shire, which would have to be pitched at well over $10 billion, would be a record size for Teva and might be too much of a stretch, one added.
Officials at Teva and Shire declined to comment.
"It's aggressive but Teva has bought large companies before. They have showed a lot of skill in digesting large companies," said Gilad Alper, an analyst at the Excellence Nessuah brokerage in Tel Aviv.
"Shire would be more complicated since it's branded and not generics and marketing would be different -- but it would not be overly ambitious."
Teva, which bought Barr for $7.5 billion in 2008, certainly has a track record of doing major acquisitions and said last month it was ready to look outside of generics for future deals.
"We believe that the same type of capabilities that we have developed in the generic markets, we can also apply to specialty," Teva's North American CEO Bill Marth told analysts during the company's second-quarter conference call.
"Now, this doesn't mean that Teva is going to necessarily run out tomorrow and chase down specialty companies ... but ... as you think of companies moving forward, you should not limit your thinking to just generic companies."
BLURRED DIVISION
A Teva-Shire deal would mark a further blurring of the dividing line between branded and cheaper generic medicines at a time when big drugmakers like Pfizer and GlaxoSmithKline are increasingly moving into the generic space. Citigroup analyst John Boris is convinced acquiring Shire would make strategic and financial sense for Teva.
In a note last week he estimated a deal closing by end-2009 would be modestly dilutive in 2010 and accretive to earnings thereafter, assuming Teva paid the same 40 percent premium as for Barr and offered 40 percent equity and 60 percent cash.
With Shire's market value at $9.3 billion that would imply a price of $13 billion. But Excellence's Alper thinks the premium might not be so large, given a recent rally in Shire shares.
Teva's market capitalization is $46 billion.
Bringing Shire into the fold would make Teva a major player in hyperactivity drugs -- it already sells a generic version of Shire's Adderall XR treatment -- and add a range of drugs for rare diseases that Shire picked up by buying TKT four years ago.
Shire is relatively rare beast, since it is one of the few mid-sized drugmakers in Europe that is available to be bought and not held by a family trust.
As a result, it is often in the rumor mill. Previous suggested buyers have included British rivals AstraZeneca and Glaxo.
But Shire also has the firepower to make a chunky acquisition itself and Ian Wainwright, an analyst at Canaccord Adams, thinks a bid for the likes of Swiss biotech group Actelion could be a potential defensive move.
Recent TEVA News
- Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024 • Business Wire • 07/02/2024 10:00:00 PM
- Les nouvelles données portant sur AJOVY® (fremanezumab) dans la prévention de la migraine remettent en question les pauses thérapeutiques • Business Wire • 06/28/2024 10:34:00 PM
- Neue Daten zu AJOVY® (Fremanezumab) zur Migräneprävention stellen Behandlungspausen in Frage • Business Wire • 06/28/2024 07:41:00 PM
- New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses • Business Wire • 06/28/2024 03:30:00 PM
- Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020 • Business Wire • 06/25/2024 12:00:00 PM
- Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States • Business Wire • 06/24/2024 01:50:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 12:03:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 12:00:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:41:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:38:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:27:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:23:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:20:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:17:48 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:14:54 AM
- Adobe Soars 15% Pre-Market; Visa and Mastercard Encounter Hurdles in $30 Billion Agreement, and More • IH Market News • 06/14/2024 11:21:47 AM
- Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/04/2024 08:05:00 PM
- New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate) • Business Wire • 06/01/2024 06:25:00 PM
- Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024 • Business Wire • 06/01/2024 06:20:00 PM
- Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) • Business Wire • 05/29/2024 10:38:00 PM
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. • Business Wire • 05/21/2024 12:25:00 AM
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. • GlobeNewswire Inc. • 05/21/2024 12:25:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2024 12:36:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:30:32 PM
- Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations • Business Wire • 05/15/2024 12:15:00 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM